AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer

pharmafile | June 22, 2018 | News story | Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma 

In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in the country from the Drug Controller General of India (DCGI) to become the first available immunotherapy for the treatment of unresectable non-small cell lung cancer (NSCLC).

Imfinzi is a human monoclonal antibody which functions by binding to the PD-L1 protein, which tumours are known to use to evade attacks from the body’s immune system, and blocks its interaction with PD-1 and CD80. This latest approval follows the decision taken by the FDA in February this year to authorise the sale of the drug in the US in NSCLC after it demonstrated improvements in median progression-free survival of 11.2 months.

Approval in NSCLC is considered a considerable boost to the potential success of a cancer therapy, with the condition accounting for 85% of all lung cancer cases, which is itself one of the most common cancers. This is particularly important in India, where the disease is the most common cancer across the country in men and is responsible for more deaths than any other, at 13.7%.

“The import and market permission for durvalumab for unresectable stage III non-small cell lung cancer and locally advanced or metastatic urothelial carcinoma is a significant milestone for patients who have currently limited treatment options,” commented Gagan Singh, Managing Director at AstraZeneca Pharma India. “In India, approximately one third of patients with NSCLC are present with Stage III disease and we are excited to bring the first immunotherapy into this setting for patients.”

Matt Fellows

Related Content

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

Latest content